Jubilant Biosys Innovative Research Services Pte. Limited (JBIRSPL), a Singapore-based subsidiary of Jubilant Biosys Limited, has entered into a definitive agreement with Pierre Fabre SA and its affiliates. Under this agreement, JBIRSPL will acquire an 80% stake in JASMIN, a newly incorporated company in France, while Pierre Fabre will retain the remaining 20%. Upon completion, JASMIN will take over Pierre Fabre’s R&D Centre at Saint-Julien-en-Genevois, including its research site and ongoing R&D activities. Additionally, JBIRSPL will formalize a Shareholders’ Agreement and transition agreements with Pierre Fabre.
This move significantly strengthens Jubilant Biosys Limited’s presence in Europe, particularly in Biologics and Antibody Drug Conjugate (ADC) development. The integration aligns with the company’s strategy to expand its global footprint and enhance service offerings.
Jubilant is expanding into the high-growth Antibody-Drug Conjugates (ADC) and XDC market, which is projected to surpass $1.4 billion, driven by next-generation therapies. This move enhances Jubilant’s ADC capabilities, integrating advanced payload-linker synthesis, bioconjugation, and analytical services with its existing chemistry expertise. Additionally, the acquisition brings a highly skilled team with a strong track record in ADC/XDC development, further strengthening Jubilant’s ability to advance clinical candidates.
By establishing a strategic European presence, Jubilant gains proximity to major pharmaceutical markets in Europe and the U.S., fostering stronger collaborations with biotech and pharma companies. This expansion also diversifies its customer base, creating cross-selling opportunities with both small-to-mid biotech firms and large pharmaceutical innovators. Moreover, the cost-effective delivery model, which combines Saint-Julien-en-Genevois’ biologics expertise with Jubilant’s small-molecule capabilities in India, offers global clients an integrated and efficient service solution.
Commenting on the acquisition, Giuliano Perfetti, CEO & Managing Director, Jubilant Biosys Limited, stated: “This collaboration with Pierre Fabre marks a significant step in our European expansion. Our new R&D Centre in Saint-Julien-en-Genevois will be a hub for biologics and ADC innovation, enhancing our ability to serve both biotech and large pharmaceutical companies. By integrating expertise from our 1,200 scientists in India with the advanced biologics capabilities in France, we are building a comprehensive CRDMO model to accelerate drug discovery and development.”
Jubilant Biosys Limited is a global provider of integrated drug discovery and contract development services. With research centers in Bengaluru, Noida, and Greater Noida, the company offers end-to-end services in medicinal chemistry, computational biology, GMP and non-GMP scale-up, DMPK, pharmacology, and toxicology. Jubilant Biosys has successfully contributed to over 85 programs across therapeutic areas such as oncology, metabolic disorders, pain management, CNS, and rare diseases.
Jubilant Pharmova Limited is a multinational pharmaceutical company specializing in radiopharmaceuticals, allergy immunotherapy, sterile injectable CDMO, and CRDMO services. It operates multiple manufacturing facilities serving regulated markets worldwide, employing approximately 5,500 professionals across its global operations.
Founded in 1961, Pierre Fabre is a French multinational company focused on pharmaceuticals and dermo-cosmetics. With over 10,000 employees and annual revenues exceeding €2.8 billion, the company is a recognized leader in oncology and dermatology. Its Saint-Julien-en-Genevois R&D Centre, established in 1990, specializes in immuno-oncology and antibody-drug conjugates (ADCs), leveraging cutting-edge research in macrophage reactivation therapies for cancer treatment.
